Pharma Research, led by CEO Ji-Hoon Son, announced on the 30th that it held the 'Total Aesthetic Solution Symposium' (TAS Symposium) at the Kempinski Hotel in Thailand on the 28th, commemorating the launch of its botulinum toxin product, 'Lientox'. This launch represents a significant step in Pharma Research's strategy to enhance its presence in the Thai aesthetic market.

The symposium attracted approximately 300 local medical professionals, demonstrating robust interest in the newly launched Lientox, alongside established products such as the Polynucleotide-based skin booster 'Rejuran', HA filler 'Cleaviel', and the joint injection product 'Conjuran'. This event underscores the company's emphasis on offering a comprehensive suite of aesthetic solutions tailored to local market needs.

By introducing Lientox to a market where Rejuran and Cleaviel have already gained stability, Pharma Research aims to define its total aesthetic solution strategy more concretely. The integration of these products presents an opportunity for medical professionals to broaden their treatment options, particularly in skin improvement, volume enhancement, and contouring.

Moreover, the inclusion of the PN-based joint injection 'Conjuran' illustrates Pharma Research's directive to extend its business model beyond aesthetics into the medical sector, reinforcing the company's commitment to versatile applications of its technologies.

A representative from Pharma Research stated, 'Thailand is a core market where the competitiveness of our products has already been proven, especially with Rejuran and Cleaviel. Through the launch of Lientox, we seek to strengthen synergies with our existing portfolio and offer a more complete integrated solution.'

This strategic expansion into a validated market not only enhances Pharma Research's competitive positioning but also signals the broader trend of aesthetic companies exploring diverse treatment vectors, setting an industry benchmark for integrated offerings.